Chondroitin sulfate proteoglycan 4 (CSPG4) bearing oncofetal chondroitin sulfate (ofCS) (CSPG4-ofCS)

Chondroitin sulfate proteoglycan 4 (CSPG4), also known as NG2, is a large transmembrane proteoglycan that plays a critical role in cell survival, migration, and angiogenesis within the tumor microenvironment (Source: UniProt Q6UVK1). In many malignancies, CSPG4 undergoes a specific post-translational modification resulting in the expression of oncofetal chondroitin sulfate (ofCS), a unique glycosaminoglycan chain (Source: Salanti et al., Nature Communications, 2015). This ofCS modification is highly prevalent across various solid tumors and hematological cancers but is restricted to the placenta in healthy adults, making it a highly specific target for cancer therapy (Source: Clausen et al., Frontiers in Oncology, 2020). Therapeutic strategies, such as those utilizing the malaria-derived protein rVAR2, exploit this specificity to deliver potent cytotoxics or engineer CAR T cells directly to the tumor site (Source: Seiler et al., Cancer Cell, 2017). By targeting the glycoform rather than just the protein backbone, these therapies aim to minimize off-tumor toxicity while maintaining broad efficacy across multiple cancer types.

Other names

NG2Melanoma-associated chondroitin sulfate proteoglycanMCSPHigh molecular weight-melanoma associated antigenHMW-MAAofCS-CSPG4Oncofetal CSPG4

The mechanism of action involves the specific recognition and high-affinity binding of the malaria-derived protein rVAR2 to the oncofetal chondroitin sulfate (ofCS) chains attached to the CSPG4 protein backbone. This binding event is used to deliver cytotoxic payloads, such as monomethyl auristatin E (MMAE), directly into cancer cells via receptor-mediated endocytosis, or to direct chimeric antigen receptor (CAR) T cells to recognize and eliminate ofCS-positive tumor cells (Source: Salanti et al., Nature Communications, 2015; Agerbæk et al., Molecular Cancer Therapeutics, 2018).